Take 1mg finasteride daily as the standard approach; adjust only if side effects occur. Many users experiment unnecessarily with doses and methods, complicating treatment.
A 42-year-old experienced significant hair regrowth after 12 weeks on an oral combination of finasteride (1 mg) and minoxidil (2.5 mg), with noticeable improvements and no side effects. The user is considering continuing the treatment for a year due to the unexpected positive results.
PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.
The conversation is about different treatments for hair loss, including minoxidil, finasteride, RU58841, and dermarolling. The conclusion is that RU58841 and dermarolling have shown efficacy in treating hair loss through different pathways.
Way-316606 is considered a potential hair loss treatment but is avoided due to safety concerns and lack of research. Minoxidil and Finasteride are preferred as established treatments.
The conversation is about a user sharing their hair transplant results and seeking feedback. They are taking finasteride, minoxidil, oral minoxidil, vitamins, and using special shampoo to maintain their hair.
The user experienced significant hair regrowth using dutasteride daily for six months, then every other day, after stopping minoxidil. They did not use finasteride and reported no side effects.
A 37-year-old man reports significant hair regrowth using a regimen of topical minoxidil, oral finasteride, derma rolling, and saw palmetto shampoo, but notices uneven progress between the sides of his head. He theorizes that sleeping on one side might affect hair growth, but others suggest it could be unrelated to sleeping habits.
Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.
Kintor is accused of using fake pictures to promote their product, Pyrilutamide (KX826), which failed Phase 3 trials. Users express disappointment and note similar false advertising has occurred with finasteride and minoxidil.